| Drug General Information |
| Drug ID |
D06NOF
|
| Former ID |
DIB008147
|
| Drug Name |
ATI-9242
|
| Synonyms |
Antipsychotic agent (oral, psychiatric disorders), ARYx Therapeutics; Antipsychotic agent (oral, schizophrenia), ARYx Therapeutics
|
| Indication |
Schizophrenia [ICD9: 295; ICD10:F20]
|
Discontinued in Phase 2 |
[1]
|
|---|
| Company |
ARYx Therapeutics Inc
|
| Target and Pathway |
| Target(s) |
5-hydroxytryptamine 7 receptor |
Target Info |
Modulator |
[2]
|
|---|
| D(2) dopamine receptor |
Target Info |
Modulator |
[2]
|
| 5-hydroxytryptamine 2A receptor |
Target Info |
Modulator |
[3],
[2]
|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Calcium signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Serotonergic synapsehsa04015:Rap1 signaling pathway
|
|
cAMP signaling pathway
|
|
Gap junction
|
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Alcoholismhsa04020:Calcium signaling pathway
|
|
Serotonergic synapse
|
|
Inflammatory mediator regulation of TRP channels
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathwayP04374:5HT2 type receptor mediated signaling pathway
|
|
PathWhiz Pathway
|
Excitatory Neural Signalling Through 5-HTR 7 and Serotonin
|
|
Reactome
|
Serotonin receptors
|
|
G alpha (s) signalling eventsR-HSA-390651:Dopamine receptors
|
|
G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors
|
|
G alpha (q) signalling events
|
|
WikiPathways
|
Serotonin Receptor 4/6/7 and NR3C Signaling
|
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
GPCRs, OtherWP666:Hypothetical Network for Drug Addiction
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
Nicotine Activity on Dopaminergic NeuronsWP733:Serotonin Receptor 2 and STAT3 Signaling
|
|
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
|
|
SIDS Susceptibility Pathways
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
GPCRs, Other
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028165) |
|---|
| REF 2 | Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12. |
|---|
| REF 3 | Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). J Pharmacol Exp Ther. 1992 Jan;260(1):146-59. |
|---|
